{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:08:25Z","timestamp":1789214905639,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["21S11905600"],"award-info":[{"award-number":["21S11905600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC12020109"],"award-info":[{"award-number":["SHDC12020109"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010098","name":"Shanghai Association for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2022YQ027"],"award-info":[{"award-number":["2022YQ027"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004572","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","award":["2026ZD01912301"],"award-info":[{"award-number":["2026ZD01912301"]}],"id":[{"id":"10.13039\/501100004572","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jve.2026.100627","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:07:53Z","timestamp":1780531673000},"page":"100627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiviral efficacy of LNP-delivered IFN-\u03b114-ApoAI mRNA for chronic hepatitis B"],"prefix":"10.1016","volume":"12","author":[{"given":"Qunling","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conglin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jve.2026.100627_bib1","unstructured":"World Health Organization. Hepatitis B. World Health Organization Fact Sheet (Revised July 2025). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b2025 [accessed 3 March 2026]."},{"key":"10.1016\/j.jve.2026.100627_bib2","article-title":"Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B","volume":"8","author":"Roade","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"2","key":"10.1016\/j.jve.2026.100627_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/cpt.3287","article-title":"Optimal treatment based on interferon No longer makes clinical cure of chronic hepatitis B far away: an evidence-based review on emerging clinical data","volume":"116","author":"Li","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jve.2026.100627_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jve.2026.100627_bib5","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.29609","article-title":"Hepatitis B virus sensitivity to interferon-alpha in hepatocytes is more associated with cellular interferon response than with viral genotype","volume":"67","author":"Shen","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jve.2026.100627_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hep.31282","article-title":"Functional comparison of Interferon-alpha subtypes reveals potent hepatitis B virus suppression by a concerted action of Interferon-alpha and Interferon-gamma signaling","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jve.2026.100627_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.jve.2026.100627_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.jve.2026.100627_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-023-00751-6","article-title":"Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability","volume":"8","author":"Zhang","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"10432","key":"10.1016\/j.jve.2026.100627_bib10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jve.2026.100627_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2015.02.048","article-title":"Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I","volume":"63","author":"Berraondo","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jve.2026.100627_bib12","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.24306","article-title":"Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties","volume":"53","author":"Fioravanti","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jve.2026.100627_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104826","article-title":"A novel recombinant cccDNA-based mouse model with long term maintenance of rcccDNA and antigenemia","volume":"180","author":"Wu","year":"2020","journal-title":"Antivir Res"},{"issue":"1","key":"10.1016\/j.jve.2026.100627_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2287681","article-title":"An extracellular humanized IFNAR immunocompetent mouse model for analyses of human interferon alpha and subtypes","volume":"13","author":"Li","year":"2024","journal-title":"Emerg Microb Infect"},{"issue":"1","key":"10.1016\/j.jve.2026.100627_bib15","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41467-017-02304-7","article-title":"Hepatitis B virus persistence in mice reveals IL-21 and IL-33 as regulators of viral clearance","volume":"8","author":"Shen","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jve.2026.100627_bib16","first-page":"425","article-title":"[Establishment of hepatitis B virus (HBV) chronic infection mouse model by in vivo transduction with a recombinant adeno-associated virus 8 carrying 1. 3 copies of HBV genome (rAAN8-1. 3HBV)]","volume":"26","author":"Dong","year":"2010","journal-title":"Bingdu Xuebao"},{"issue":"1","key":"10.1016\/j.jve.2026.100627_bib17","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1038\/s41467-023-43078-5","article-title":"Interferon stimulated immune profile changes in a humanized mouse model of HBV infection","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jve.2026.100627_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/hep.25608","article-title":"MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jve.2026.100627_bib19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2019.12.009","article-title":"Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication","volume":"72","author":"Wang","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jve.2026.100627_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000353220","article-title":"Interferon-induced proteins with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication","volume":"6","author":"Pei","year":"2014","journal-title":"J Innate Immun"},{"issue":"9","key":"10.1016\/j.jve.2026.100627_bib21","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.4049\/jimmunol.150.9.3713","article-title":"IFN induction and associated changes in splenic leukocyte distribution","volume":"150","author":"Ishikawa","year":"1993","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.jve.2026.100627_bib22","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.4049\/jimmunol.157.7.3054","article-title":"NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection","volume":"157","author":"Salazar-Mather","year":"1996","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.jve.2026.100627_bib23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/RLU.0b013e318148afa5","article-title":"PET positive generalized lymphadenopathy and splenomegaly following interferon-alfa-2b adjuvant therapy for melanoma","volume":"32","author":"Cone","year":"2007","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.jve.2026.100627_bib24","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.ymthe.2024.12.019","article-title":"mRNA-LNPs induce immune activation and cytokine release in human whole blood assays across diverse health conditions","volume":"33","author":"Nguyen","year":"2025","journal-title":"Mol Ther"},{"issue":"6773","key":"10.1016\/j.jve.2026.100627_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/science.adr8470","article-title":"Deep generative models design mRNA sequences with enhanced translational capacity and stability","volume":"390","author":"Zhang","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.jve.2026.100627_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2018.11.003","article-title":"PASylated interferon alpha efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice","volume":"161","author":"Xia","year":"2019","journal-title":"Antivir Res"},{"issue":"5","key":"10.1016\/j.jve.2026.100627_bib27","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/biomedicines9050530","article-title":"Non-immunotherapy application of LNP-mRNA: maximizing efficacy and safety","volume":"9","author":"Vlatkovic","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jve.2026.100627_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.34133\/bmr.0017","article-title":"Development of lipid nanoparticle formulation for the repeated administration of mRNA therapeutics","volume":"28","author":"Lee","year":"2024","journal-title":"Biomater Res"},{"issue":"12","key":"10.1016\/j.jve.2026.100627_bib29","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1039\/D5NH00230C","article-title":"Influence of hydrophilic polymers on the accelerated blood clearance of mRNA lipid nanoparticles upon repeated administration","volume":"10","author":"Hassanel","year":"2025","journal-title":"Nanoscale Horiz"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664026000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664026000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:27:13Z","timestamp":1789212433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664026000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2055664026000075"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2026.100627","relation":{},"ISSN":["2055-6640"],"issn-type":[{"value":"2055-6640","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral efficacy of LNP-delivered IFN-\u03b114-ApoAI mRNA for chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2026.100627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100627"}}